MetaVia reports preclinical DA-1726 tissue distribution: highest in adipose, prolonged retention

MetaVia Inc.

Preclinical study shows DA-1726-derived radioactivity highest in adipose tissue, with broad distribution and prolonged retention through 144h.
Tissue-to-plasma ratios increased over time; greatest exposure in abdominal, subcutaneous, brown fat, and liver; minimal CNS penetration.
CEO cites Phase 1 data: 48 mg dose achieved mean 9.8 cm waist circumference reduction after 8 weeks (Day 54).
Company expects 16-week topline data in Q4 2026 and 24-week topline results in Q1 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.